Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes

Nephrology Dialysis Transplantation

Volumn 11, Issue 4, 1996, Pages 673-678

  Hannedouche, Thierry P ^a,b   Natov, Svetlozar ^a   Boitard, Christian ^a   Lacour, Bernard ^a   Grünfeld, Jean Pierre ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Angiotensin converting enzyme inhibition; Cyclosporine A; Diabetes mellitus; Glomerular filtration rate; Kidney tubule; Lithium clearance; Renal haemodynamics

Indexed keywords

CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMMUNOSUPPRESSIVE AGENT; LITHIUM; SODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029958986     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027358     Document Type: Article

References (41)

1. Assan R, Feutren G, Debrav-Sachs M et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type I diabetes mellitus. Lancet 1985; i: 67-71
2. Deray G, Benhmida M, Hoang PL et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992; 117: 578-583
3. Meyrier A. Treatment of nephrotic syndrome with cyclosporin A. What remains in 1994? Nephrol Dial Transplant 1994; 9: 596-598
4. Bennett WM. Clinical aspects of cyclosporine nephrotoxicity. In: Hitano M, ed. Nephrology. Proceedings of the XIth International Congress of Nephrology Springer-Verlag: Tokyo, 1991:564-575
5. Greenberg A, Thompson ME, Griffith BJ et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven-year follow-up. Transplantation 1990; 50: 589-593
6. Keown PA, Stiller CR, Wallace AC. Nephrotoxicity of cyclosporin A. In: Burdick JF, Racusen LC, Solez K and Williams GM, eds. Kidney Transplant Rejection: diagnosis and treatment. Marcel Dekker: New York, 1992: 637-674
7. Edwards BD, Chalmers-RJG, O'Driscoll JB et al. Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. Clin Nephrol 1994; 41: 350-356
8. Clozel JP, Fischli W. Cyclosporin-induced hypertension in marmosets: A new model of hypertension sensitive to angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1989; 14: 77-81
9. Hannedouche T, Natov S, Garev L et al. Renal haemodynamic effects of short term cyclosporin A administration in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1990; 5: 168-173
10. Feutren G, Papoz L, Assan R et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Lancet 1986; ii: 119-124
11. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1-9
12. Curtis JJ, Bubovsky M, Whelchel J et al. Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 1986, 2: 477-479
13. Myers BD, Sibley R, Newton L et al. The long term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590-600
14. Capasso G, Rosati C, Ciani F et al. The beneficial effect of atrial natriuretic peptide on cyclosporine nephrotoxicity. Am J Hypertens 1990; 3: 204-210
15. Hunley TE, Fogo A, Iwasaki S, Kon V. Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 1995; 5: 1718-1723
16. Jorkasky DK, Audet P, Shusterman N et al. Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients. Am J Kidney Dis 1992; 19: 567-572
17. Rossini M, Belloni A, Remuzzi G, Perico N. Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation. Circulation 1990; 81 (Suppl. I): 161-167
18. Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-711
19. Barros EJG, Boim MA, Ajzen H, Ramos OL, Schor N. Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int 1987; 32: 19-25
20. Meyer-Lehnert H, Schrier RW. Cyclosporine A enhances vasopressin-induced Ca2+ mobilization and contraction in mesangial cells. Kidney Int 1988; 34: 89-97
21. Rodriguez-Puyol D, Lamas S, Olivera A. Actions of cyclosporin A on cultured rat mesangial cells. Kidney Int 1989; 35: 632-637
22. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium-dependent. Am J Med 1988; 85: 134-138
23. Dieperinck H, Starklint H, Leyssac PP, Kelp E. Glomerulotubular function in cyclosporine-treated rats. A lithium clearance, occlusion time transit time and micropuncture study. Proc EDTA-ERA 1984; 2: 853-859
24. Whiting PH, Propper DJ, Simpson JG et al The use of lithium clearance measurements to assess renal tubular function in experimental and clinical cyclosporine nephrotoxicity. Transplant Proc 1988; 3 (Suppl 3): 675-680
25. Nitta K, Friedman AL, Nicasti AD, Paik S, Friedman EA. Granular juxtaglomerular cell hyperplasia caused by cyclosporine. Transplantation 1987; 44: 417-421
26. Verpooten GA, Wybo I, Pattyn VM et al. Cyclosporine nephrotoxicity: comparative cytochemical study of rat kidney and human allograft biopsies. Clin Nephrol 1986; 25: S18-S22
27. Murray BM, Paller MS, Ferris TF. Effect of Cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 34: 767-774
28. Perico N, Zoja C, Benigni F et al. Effects of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. J Pharmacol Exp Ther 1986; 239: 229-235
29. Gerkens JF, Smith AJ. Effect of captopril and theophylline treatment on cyclosporine-induced nephrotoxicity in rats. Transplantation 1985; 40: 213-214
30. Kaskel FJ, Devarajan P, Arbeit LA, Partin JS, Moore LC. Cyclosporine nephrotoxicity: sodium excretion, autoregulation, and angiotensin II. Am J Physiol 1987; 252: F733-F742
31. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83: 59-64
32. Bertani T, Ferrazzi P, Schieppati A et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40: 243-250
33. Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Drechsler S, Kramer HJ. Cellular signaling by cyclosporine A in contractile cells: Interactions with atrial natriuretic peptide. Clin Invest 1993; 71: 153-160
34. Hannedouche T, Choukroun G, Delgado A et al. Blood pressure changes induced by ciclosporin A in type I diabetes. Miner Electrolyte Metabol 1990; 16: 12-15
35. Juillerat L, Nussberger J, Ménard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564-572
36. Stern N, Lustig S, Petrasek D et al. Cyclosporin A-Induced hyperreninemic hypoaldosteronism. A model of adrenal resistance to angiotensin II. Hypertension 1987; 9: III31-III35
37. Erman A, Chen-Gal B, Zabludowski J, Rosenfeld JB. Cyclosporin A treatment enhances angiotensin converting enzyme activity in lung and serum of rats. J Pharm Pharmacol 1990; 42: 525-527
38. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 438-449
39. Berkenboom G, Brekine D, Unger P, Gulbis B, Fontaine J. Attenuation of Cyclosporine A-induced vascular toxicity by ramipril. J Cardiovasc Pharmacol 1994, 24. 17-21
40. Ferrario CM, Brosnihan KB, Diz DI, et al. Angiotensin-(1-7): A new hormone of the angiotensin system. Hypertension 1991; 18 (Suppl. 3): III126-III133
41. Szentpetery S, Richardson J, Hanrahan J, Lower RR. Cardiac transplantation without oral steroids. The McGuire VA Hospital experience. J Heart Transplant 1989; 1: 103A